Skip to main navigation

Top Navigation

About Us
- Our Company
- Contact Us
Our Pipeline
- Pipeline
  - ZN-c3
  - ZN-c5
  - ZN-d5
  - ZN-e4
- Clinical Trials
Our Approach
- Integrated Discovery Engine
- Supporting Publications
Investors & Media
Careers

Investors/Media

Press Releases

Press Releases

Year

Mar 29, 2022

Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3

Mar 22, 2022

Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis

Mar 15, 2022

Stand Up to Cancer Announces $1 Million Donation From Zentalis Pharmaceuticals To Fund Targeted Cancer Therapy Research

Mar 09, 2022

Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference

Mar 08, 2022

Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022

Feb 24, 2022

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

Feb 03, 2022

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 17 of 17

Investors/Media

Investor Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
- SEC Filings
Corporate Governance
Investor Resources

Investor Contact

Alexandra Roy
Solebury Trout
aroy@soleburytrout.com

Media Contact

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com

“The sun is but a morning star.”

Corporate Office

530 Seventh Avenue
Suite 2201
New York, NY 10018

Science Center

10835 Road to the Cure
Suite 205
San Diego, CA 92121

For More Information

1-212-433-3791
info@zentalis.com

Footer

Privacy Policy
Terms of Use
Expanded Access Policy
Site Map

Copyright © 2022 Zentalis Pharmaceuticals. All Rights Reserved.